Vitamin C ( DrugBank: Vitamin C )

6 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
10	シャルコー・マリー・トゥース病	1
192	コケイン症候群	1
206	脆弱Ｘ症候群	2
210	単心室症	1
211	左心低形成症候群	1
212	三尖弁閉鎖症	1

10. シャルコー・マリー・トゥース病

臨床試験数 : 41 / 薬物数 : 46 - (DrugBank : 9) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 15

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00484510 (ClinicalTrials.gov)	April 2007	8/6/2007	High Dose Ascorbic Acid Treatment of CMT1A	A Randomized, Placebo-controlled, Double Masked 120 Subject Futility Design Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A.	Charcot-Marie-Tooth Disease, Type Ia	Drug: Ascorbic acid (Vitamin C);Drug: placebo	Wayne State University	Muscular Dystrophy Association;Charcot-Marie-Tooth Association	Completed	13 Years	70 Years	Both	110	Phase 2/Phase 3	United States

192. コケイン症候群

臨床試験数 : 4 / 薬物数 : 7 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 51

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1900026719	2019-11-01	2019-10-19	Clinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndrome	Clinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndrome	Cockayne's syndrome	test group:Vitamin C and Quercetin;	The First Medical Center of PLA General Hospital	NULL	Pending	6	13	Both	test group:20;		China

206. 脆弱Ｘ症候群

臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-005460-42-ES (EUCTR)	07/07/2016	20/04/2016	Clinical trial to evaluate ascorbic acid (vitamin C) and tocopherol (vitamin E) in combination versus placebo for the treatment of cognitive and behavioral disorders in children with fragile x syndrome	Phase III clinical trial, double-blind, cross-way, to evaluate the safety and efficacy ascorbic acid (vitamin C) and tocopherol (vitamin E) combination versus placebo for the treatment of cognitive and behavioral disorders in children with fragile x syndrome	Fragile x syndrome MedDRA version: 19.0;Level: PT;Classification code 10017324;Term: Fragile X syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: Vitamin C INN or Proposed INN: Vitamin C Other descriptive name: ACIDUM ASCORBICUM D6 Product Name: Vitamin E INN or Proposed INN: Vitamin E Other descriptive name: TOCOPHERYL ACETATE	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	NULL	Not Recruiting			Female: no Male: yes		Phase 3	Spain
2	NCT01329770 (ClinicalTrials.gov)	December 2010	29/3/2011	Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome	Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X Syndrome	Fragile X Syndrome	Dietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E);Dietary Supplement: Placebo	Yolanda de Diego Otero	NULL	Completed	6 Years	18 Years	Male	30	Phase 2	Spain

210. 単心室症

臨床試験数 : 51 / 薬物数 : 53 - (DrugBank : 22) / 標的遺伝子数 : 32 - 標的パスウェイ数 : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00974025 (ClinicalTrials.gov)	June 2009	9/9/2009	Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients	Vitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan Palliation	Fontan Procedure;Hypoplastic Left Heart Syndrome;Tricuspid Atresia	Dietary Supplement: Vitamin C;Dietary Supplement: Placebo	University of Michigan	Griese-Hutchinson Champions for Children's Hearts Investigator Award	Completed	8 Years	25 Years	All	53	N/A	United States

211. 左心低形成症候群

臨床試験数 : 22 / 薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00974025 (ClinicalTrials.gov)	June 2009	9/9/2009	Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients	Vitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan Palliation	Fontan Procedure;Hypoplastic Left Heart Syndrome;Tricuspid Atresia	Dietary Supplement: Vitamin C;Dietary Supplement: Placebo	University of Michigan	Griese-Hutchinson Champions for Children's Hearts Investigator Award	Completed	8 Years	25 Years	All	53	N/A	United States

212. 三尖弁閉鎖症

臨床試験数 : 5 / 薬物数 : 6 - (DrugBank : 6) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 12

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00974025 (ClinicalTrials.gov)	June 2009	9/9/2009	Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients	Vitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan Palliation	Fontan Procedure;Hypoplastic Left Heart Syndrome;Tricuspid Atresia	Dietary Supplement: Vitamin C;Dietary Supplement: Placebo	University of Michigan	Griese-Hutchinson Champions for Children's Hearts Investigator Award	Completed	8 Years	25 Years	All	53	N/A	United States

先頭へ